Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELN584164
- Development stage
- Unknown
- Lead developer
- Perrigo
01
Overview
ELN584164 is an early-stage research compound referenced in intellectual property and asset-transfer documents associated with Elan/Prothena’s neurodegenerative disease programs, but no public data describing its molecular structure, pharmacological target, therapeutic indication, or development status are available. It appears only as part of a list of related compounds (including ELN584092, ELN584105, ELN584095, and ELN584090) in corporate filings and IP agreements, with no associated clinical trials or mechanistic characterization, suggesting it did not progress to late preclinical or clinical development in a way that generated public disclosures.
Beyond the preview
Go deeper on ELN584164.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELN584164.